{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:08:11Z","timestamp":1789546091400,"version":"build-2803163510"},"reference-count":22,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction\u2013associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids. Peak triglycerides reached 2329\u2005mg\/dL (Syst\u00e8me International [SI]: 26.3\u2005mmol\/L; reference range, &amp;lt;177\u2005mg\/dL [SI: &amp;lt;2\u2005mmol\/L]). Comorbidities included poorly controlled diabetes, recurrent hypoglycemia, and steatotic liver disease with moderate fibrosis. Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated. This achieved sustained triglyceride normalization to 213\u2005mg\/dL (SI: 2.4\u2005mmol\/L), weight loss, glycemic improvement, hypoglycemia resolution, improved liver elastography parameters, and insulin cessation without pancreatitis recurrence. This case demonstrates that glucagon-like peptide-1 receptor agonists warrant consideration in treatment-resistant hypertriglyceridemia with prior pancreatitis when conventional therapy fails, challenging traditional contraindications in carefully selected patients under multidisciplinary care.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag274","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:13:33Z","timestamp":1788520413000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonists as adjunctive therapy in refractory hypertriglyceridemia following recurrent pancreatitis"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2660-1217","authenticated-orcid":false,"given":"Daisuke","family":"Miura","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Monash Health , Clayton, VIC 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University , Clayton, VIC 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju E","family":"Joham","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Monash Health , Clayton, VIC 3168 ,","place":["Australia"]},{"name":"Monash Centre for Health Research and Implementation, Faculty of Medicine Nursing and Health Sciences, Monash University , Clayton, VIC 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Braude","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Monash Health , Clayton, VIC 3168 ,","place":["Australia"]},{"name":"School of Clinical Sciences, Monash University , Clayton, VIC 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6228-2654","authenticated-orcid":false,"given":"Chau Thien","family":"Tay","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Monash Health , Clayton, VIC 3168 ,","place":["Australia"]},{"name":"Monash Centre for Health Research and Implementation, Faculty of Medicine Nursing and Health Sciences, Monash University , Clayton, VIC 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"5","key":"2026091603525040400_luag274-B1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","article-title":"Hypertriglyceridemia and acute pancreatitis","volume":"20","author":"Yang","year":"2020","journal-title":"Pancreatology"},{"issue":"1","key":"2026091603525040400_luag274-B2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12876-025-03954-4","article-title":"A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis","volume":"25","author":"Lu","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"2026091603525040400_luag274-B3","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4721357","article-title":"Management of hypertriglyceridemia-induced acute pancreatitis","volume":"2018","author":"Garg","year":"2018","journal-title":"Biomed Res Int"},{"issue":"9","key":"2026091603525040400_luag274-B4","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026091603525040400_luag274-B5","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/ATVBAHA.121.316311","article-title":"GLP-1 (glucagon-like peptide-1) is physiologically relevant for chylomicron secretion beyond its known pharmacological role","volume":"41","author":"Nahmias","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2026091603525040400_luag274-B6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1\u2013based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"9","key":"2026091603525040400_luag274-B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103116","article-title":"Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: a propensity-matched global federated TriNetX database-based retrospective cohort study","volume":"18","author":"Nassar","year":"2024","journal-title":"Diabetes Metab Syndr"},{"issue":"Suppl 2","key":"2026091603525040400_luag274-B8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1 receptor agonist\u2013based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026091603525040400_luag274-B9","volume-title":"Endotext","author":"Feingold"},{"issue":"1","key":"2026091603525040400_luag274-B10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1373\/clinchem.2007.093492","article-title":"Association of cystic fibrosis transmembrane conductance regulator mutation\/variant\/haplotype and tumor necrosis factor promoter polymorphism in hyperlipidemic pancreatitis","volume":"54","author":"Chang","year":"2008","journal-title":"Clin Chem"},{"issue":"49","key":"2026091603525040400_luag274-B11","first-page":"825","article-title":"The diagnosis and treatment of hypertriglyceridemia","volume":"116","author":"Parhofer","year":"2019","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"2026091603525040400_luag274-B12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.bbalip.2011.10.003","article-title":"Hypertriglyceridemia secondary to obesity and diabetes","volume":"1821","author":"Subramanian","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"19","key":"2026091603525040400_luag274-B13","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"5519","key":"2026091603525040400_luag274-B14","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"issue":"6","key":"2026091603525040400_luag274-B15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0955-2863(02)00284-X","article-title":"Niacin and cholesterol: role in cardiovascular disease","volume":"14","author":"Ganji","year":"2003","journal-title":"J Nutr Biochem"},{"issue":"4","key":"2026091603525040400_luag274-B16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.mol.0000236363.63840.16","article-title":"Why do omega-3 fatty acids lower serum triglycerides?","volume":"17","author":"Harris","year":"2006","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"2026091603525040400_luag274-B17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4093\/dmj.2022.0198","article-title":"New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"issue":"4","key":"2026091603525040400_luag274-B18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40256-025-00726-z","article-title":"The efficacy and safety of GLP-1 receptor agonists in the modification of cardiovascular morbidity in patients with obesity without diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials involving 32,884 patients","volume":"25","author":"Tanashat","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"2026091603525040400_luag274-B19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/ATVBAHA.115.305479","article-title":"GLP-1, an important regulator of intestinal lipid metabolism","volume":"35","author":"Dallinga-Thie","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2026091603525040400_luag274-B20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"11","key":"2026091603525040400_luag274-B21","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001890","article-title":"Successful use of glucagon-like peptide-1 receptor agonist in a patient with recurrent hypertriglyceridemia-induced pancreatitis","volume":"12","author":"Guralwar","year":"2025","journal-title":"ACG Case Rep J"},{"issue":"4","key":"2026091603525040400_luag274-B22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/10\/luag274\/71115198\/luag274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/10\/luag274\/71115198\/luag274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:53:01Z","timestamp":1789545181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag274\/8800977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag274","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,3]]},"article-number":"luag274"}}